WALTHAM, Mass. — Korsana Biosciences, Inc., a biotechnology company focused on discovering and developing therapies for neurodegenerative diseases, has appointed Mark Vignola, Ph.D., as chief financial officer.
Dr. Vignola brings more than 15 years of leadership experience in corporate finance across the biotechnology sector, with a track record of guiding companies through major strategic and financial milestones.
“We are excited to welcome Mark as our Chief Financial Officer, with his extensive experience as a strategic financial leader to biotech companies and strong track record of advancing companies through major inflection points,” said Jonathan Violin, Ph.D., President and Chief Executive Officer of Korsana. “Mark is an outstanding addition to the executive team and will undoubtedly help our growing organization advance our pipeline of potential best-in-class therapies for neurodegenerative disorders.”
Dr. Vignola said he looks forward to supporting the company’s efforts to advance new treatment options for patients with neurodegenerative diseases.
“I am thrilled to join Korsana and help support our mission to deliver best-in-class treatment options to patients who deserve better,” said Dr. Vignola. “We are well positioned to advance the next generation of therapies for Alzheimer’s disease and other neurodegenerative disorders, with a clear path to long-term growth and value creation. I look forward to partnering with the executive team and the Board of Directors.”
Most recently, Dr. Vignola served as chief financial officer of Terns Pharmaceuticals, where he led the company’s crossover financing, initial public offering, and multiple follow-on offerings.
Before joining Terns, he was chief financial officer at Applied Therapeutics, a clinical-stage biopharmaceutical company, where he oversaw several financing rounds. Earlier in his career, Dr. Vignola served as head of corporate development and investor relations at Intercept Pharmaceuticals and worked as a biotechnology equity research analyst at Needham & Company.
Dr. Vignola earned a B.S. in Biology from Boston College and a Ph.D. in Molecular Genetics and Microbiology from Duke University.
